摘要
近十年来,关于获得性再生障碍性贫血(AA)发病机制及治疗的研究有了很大进展,普遍公认的治疗方法有.免疫抑制剂联合治疗(IST)和同种异基因造血干细胞移植(Allo-SCT),使本病的预后有了明显的改善。儿童极严重再障的5年生存率已从20世纪80年代的37%上升到90年代的83%,年龄%20岁重型再障患者10年生存率达73%,21~30岁者达75%,31~40岁者达66%,〉40岁者达47%。以下将分述近年来在这方面的进展及临床应用。
出处
《国际输血及血液学杂志》
CAS
2009年第1期15-18,共4页
International Journal of Blood Transfusion and Hematology
参考文献12
-
1Kurre P, Johnson FL, Deeg HJ, Diagnosis and treatment of children with Aplastic Anemia. Pediatr Blood Cancer, 2005:45 (6) : 770-780.
-
2Bacigalupo A. Aplastic Anemia: Pathogenesis and treatment. American Society of Haematology Education program book, 2007: 23-28.
-
3Gluckman E, Devergie A, Poros A,et al. Results of Immunosuppressive in 170 cases of severe Aplastic Anemia: Report of the European group of Bone Marrow Transplant (EBMT). Br J Haematol, 1982,51(4):541-550.
-
4Camitta BM, Thomas ED, Nathan DG,et al. Severe Aplastic Anemia. A prospective study of the effect of early marrow transplantation on Acute mortality. Blood, 1976,48(1):63-70.
-
5Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+, CD25 +, foxp3 + T Regulatory Cells in Acquired Aplastic Anemia. Blood, 2007,110(5) :1603-1606.
-
6Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of Aplastic Anemia. Blood, 2006, 108(8) :2509-2519.
-
7Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood, 2006,107(10) :3983-3991.
-
8Locasciulli A, Oneto R, Bacigalupo A, et al. Severe Aplastic Anemia working party of the European Blood and Marrow Transplant Group. Outcome of patients with Acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade. A report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 2007,92(1) :11-18.
-
9Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse Outcome and more chronic GVHD with peripheral Blood progenitor cells than Marrow in HLA matched sibling donor transplants for young patients with severe Acquired Aplastic Anemia. Blood, 2007,110(4) : 1397-1400.
-
10Deeg Hj, Amylon ID, Harris RE, et al. Marrow Transplants from unrelated donors for patients with Aplastic Anemia. Minimum effective dose of Total Body irradiation Biol. Blood Marrow Transplant,2001,7(4) :208-215.
同被引文献15
-
1杨朴.环孢霉素A 康力龙治疗慢性再生障碍性贫血[J].医药论坛杂志,2004,25(16):15-16. 被引量:3
-
2Audino AN,Blatt J,Carcamo B,et al.High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children[J].Pediatr Blood Cancer,2010,54(2):269-272.
-
3Bing H,Siyi Y,Wei Z,et al.The use of anti-human T lymphocyte porcine immunoglobulin and cyclosporine a to treat patients with acquired severe aplastic anemia[J].Acta Haematol,2010,124(4):245-250.
-
4Jiang S,Wang Y,Shi W,et al.The benefit of ATG in immunosuppressive therapy of children with moderate aplastic anemia[J].Pediatr Hematol Oncol,2009,26(5):313-320.
-
5Chang MH,Kim KH,Kim HS,et al.Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia[J].Eur J Haematol,2010,84(2):154-159.
-
6Kamio T,Ito E,Ohara A,et al.Relapse of aplastic anemia in children after immunosuppressive therapy:a report from the Japan Childhood Aplastic Anemia Study Group[J].Haematologica,2011,96(6):814-819.
-
7Tichelli A,Schrezenmeier H,Socié G,et al.A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG),cyclosporine,with or without G-CSF:a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation[J].Blood,2011,117(17):4434-41.
-
8邓家栋 杨崇礼 杨天楹 等.临床血液学[M].上海:上海科学技术出版社,2001.1085-1090.
-
9桑玉旗.环孢素A治疗再生障碍性贫血的疗效因素分析[J].临床血液学杂志,2008,21(3):268-269. 被引量:2
-
10张乃红.环孢霉素A治疗再生障碍性贫血的疗效和机制[J].中华血液学杂志,1998,19(4):218-220. 被引量:79
二级引证文献6
-
1周明,肖佩玲,罗科玲,陈建军.丙种球蛋白联合环孢素A、雄激素治疗再生障碍性贫血临床观察[J].医学临床研究,2011,28(9):1665-1667. 被引量:1
-
2魏丹娜,吴少娜.甲巯咪唑治疗甲亢致再生障碍性贫血患者的护理分析[J].包头医学院学报,2015,31(6):121-122. 被引量:3
-
3许海平.左归丸加减治疗再生障碍性贫血[J].黑龙江中医药,2015,44(2):45-46. 被引量:1
-
4范彩霞,韦湘.甲巯咪唑致重型再生障碍性贫血伴感染患者的药学监护[J].中国临床药学杂志,2017,26(1):53-56. 被引量:1
-
5卞竹利,乔晓红,谢晓恬,石苇,卢双龙,李威,周宁,周晓迅.不同剂量丙种球蛋白辅助治疗重型再生障碍性贫血疗效分析[J].临床儿科杂志,2017,35(12):914-917. 被引量:8
-
6张莉莉,郭春荣,朱荣荣,黄文慧,彭垠婷,王冰.左归丸对糖皮质激素致肾阴虚证的初步实验研究[J].数理医药学杂志,2018,31(3):317-320. 被引量:3
-
1何薇,谢晓恬.获得性再生障碍性贫血发病机制研究最新进展[J].中华实用儿科临床杂志,2016,31(3):238-240. 被引量:3
-
2儿童获得性再生障碍性贫血在免疫抑制治疗后进展为骨髓增生异常综合征和急性髓性白血病的危险因素[J].中华医学信息导报,2002,17(16):13-13.
-
3黄素芳,冷淑梅,刘喜荣.获得性再生障碍性贫血45例临床分析[J].哈尔滨医科大学学报,1998,32(1):64-65.
-
4刘家庆,朱玉霞.获得性再生障碍性贫血的免疫发病机制[J].中国医学创新,2012,9(6):156-158. 被引量:1
-
5王耀平.获得性再生障碍性贫血发病机制及治疗进展[J].实用医院临床杂志,2008,5(4):34-36.
-
6郭素娟.浅谈儿童获得性再生障碍性贫血的中西医结合治疗[J].内蒙古中医药,2011,30(5):71-72. 被引量:3
-
7袁烨,邵宗鸿.获得性再生障碍性贫血发病机制的研究进展[J].国际输血及血液学杂志,2006,29(3):200-203. 被引量:9
-
8麻柔.免疫介导的造血抑制与骨髓衰竭[J].中国中西医结合杂志,2010,30(3):334-336. 被引量:13
-
9林兰,徐之良.儿童获得性再生障碍性贫血的诊疗进展[J].职业与健康,2016,32(20):2877-2880. 被引量:2
-
10胡南霞,刘毅,李艳君,丁毅伟,郭宏岗,沈建良,马聪.病毒性肝炎与获得性再生障碍性贫血关系的病例-对照研究Meta分析[J].医学研究杂志,2015,44(11):105-110. 被引量:2